-+ 0.00%
-+ 0.00%
-+ 0.00%

Embla Medical Q2 FY26 net profit rises 39% to USD 29 million; sales climb 11% to USD 259 million

PUBT·07/21/2026 05:04:39
Listen to the news
Embla Medical Q2 FY26 net profit rises 39% to USD 29 million; sales climb 11% to USD 259 million
  • Embla Medical Q2 2026 sales rose 11% to USD 259 million, with 6% organic growth.
  • Net profit climbed 39% to USD 29 million, lifting the net profit margin to 11%.
  • EBITDA increased to USD 58 million; the margin widened 1 percentage point to 22%.
  • Free cash flow rose to USD 31 million, equal to 12% of sales; NIBD/EBITDA before special items stood at 2.2x.
  • Full-year organic sales growth outlook narrowed to 5%-7%; EBITDA margin guidance before special items reiterated at 20%-22%.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Embla Medical hf. published the original content used to generate this news brief on July 21, 2026, and is solely responsible for the information contained therein.